|
US2013274486A1
|
|
Process for the preparation of nebivolol
|
|
CN103764205A
|
|
Device for automatic injection of drug doses
|
|
WO2013018053A1
|
|
Process for the preparation of epoxides as intermediates for the synthesis of nebivolol
|
|
WO2011141419A1
|
|
Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
|
|
CA2798707A1
|
|
Association of xanthine oxidase inhibitors and statins and use thereof
|
|
WO2011141381A1
|
|
Association of xanthine oxidase inhibitors and calcium antagonists and use thereof
|
|
WO2011111006A2
|
|
Device for the automatic injection of two doses of a medicament
|
|
EP2534142A1
|
|
Process for the preparation of nebivolol
|
|
BRPI0713343A2
|
|
Pharmaceutical compositions containing anti-idiolipic monoclonal antibody anti-ca-125 and aluminum
|
|
WO2007063124A1
|
|
Use of a compound comprising a camptothecin derivative for preparing pharmaceutical formulations useful in the treatment of melanoma
|
|
TW200719900A
|
|
N-hydroxyamides ω-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations
|
|
TW200724529A
|
|
Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
|
|
BRPI0505508A
|
|
pharmaceutical composition containing zofenopril and hctz for the treatment of hypertension
|
|
EA012845B1
|
|
Pharmaceutical compositions comprising zofenopril and hctz for treating hypertension
|
|
WO2005011639A2
|
|
Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use
|
|
MY141243A
|
|
Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
|
|
PL338237A1
|
|
Pharmaceutic composition containing vitamin d and calcium salt as well as method of obtaining same
|
